sarepta therapeutics fda

News

Sarepta Will Resume Gene Therapy Shipments

FDA Says Sarepta Can Resume Gene Therapy in Some Patients

In a major win for Sarepta Therapeutics Inc., US regulators are recommending that patients who can walk be allowed to take its gene therapy Elevidys again.

· 1h · on MSN

Sarepta will resume gene therapy shipments after FDA review of recent patient death

· 2h

FDA allows Sarepta to resume some Elevidys shipments

Healthcare earnings: UnitedHealth delays, Sarepta's FDA probe

UnitedHealth (UNH) delayed its earnings report amid rising medical costs and is now set to report second quarter results on ...

Sarepta Therapeutics to Lift Pause on Shipments of Duchenne Treatment Elevidys

Sarepta Therapeutics said the Food and Drug Administration informed the company it can lift a voluntary pause on shipments of Elevidys for ambulatory patients with Duchenne. The company said Monday ...

10hon MSN

Sarepta Stock Rises Despite Downgrade and FDA Probe. The Crisis Explained.

Sarepta shares gained even though the U.S. Food and Drug Administration said late Friday that it was probing the death of an ...

News Nation on MSN8h

Parents urge FDA to restore gene therapy after distribution pause

A recent FDA investigation has paused further distribution of Elevidys, following reports of at least three patient deaths.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results